Enhanced oral bioavailability of breviscapine after encapsulation in a liposomal formulation.
This report firstly describes the pharmacokinetic study of liposomal breviscapine (LB) after oral administration in rats. The mean Cmax and AUC(0-->t) of LB were 3.3 and 3.1-fold higher than those of breviscapine solution (BS). The oral absorption of breviscapine was significantly increased after encapsulation in the liposomal formulation.
Department of Pharmaceutical Science, School of Pharmacy, Shenyang Pharmaceutical University, Liaoning, PR China. effzhj@sina.com
H J
HJ
Zhong
Y J
YJ
Deng
B H
BH
Yang
C L
CL
Li
S
S
Du
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D004337:Drug Carriers; D004339:Drug Compounding; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008081:Liposomes; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D000925:Anticoagulants; D004337:Drug Carriers; D005419:Flavonoids; D008081:Liposomes; C061097:breviscapine